CA2442909C - Multimerization of hiv-1 vif protein as a therapeutic target - Google Patents

Multimerization of hiv-1 vif protein as a therapeutic target Download PDF

Info

Publication number
CA2442909C
CA2442909C CA2442909A CA2442909A CA2442909C CA 2442909 C CA2442909 C CA 2442909C CA 2442909 A CA2442909 A CA 2442909A CA 2442909 A CA2442909 A CA 2442909A CA 2442909 C CA2442909 C CA 2442909C
Authority
CA
Canada
Prior art keywords
vif
seq
hiv
protein
peptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2442909A
Other languages
English (en)
French (fr)
Other versions
CA2442909A1 (en
Inventor
Hui Zhang
Roger Pomerantz
Bin Yang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Thomas Jefferson University
Original Assignee
Thomas Jefferson University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Thomas Jefferson University filed Critical Thomas Jefferson University
Publication of CA2442909A1 publication Critical patent/CA2442909A1/en
Application granted granted Critical
Publication of CA2442909C publication Critical patent/CA2442909C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C12N2740/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/82—Proteins from microorganisms
    • Y10S530/826—Viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Communicable Diseases (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CA2442909A 2001-04-06 2002-04-08 Multimerization of hiv-1 vif protein as a therapeutic target Expired - Fee Related CA2442909C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US28227001P 2001-04-06 2001-04-06
US60/282,270 2001-04-06
PCT/US2002/011218 WO2002081504A2 (en) 2001-04-06 2002-04-08 Multimerization of hiv-1 vif protein as a therapeutic target

Publications (2)

Publication Number Publication Date
CA2442909A1 CA2442909A1 (en) 2002-10-17
CA2442909C true CA2442909C (en) 2011-11-29

Family

ID=23080751

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2442909A Expired - Fee Related CA2442909C (en) 2001-04-06 2002-04-08 Multimerization of hiv-1 vif protein as a therapeutic target

Country Status (8)

Country Link
US (4) US6653443B2 (https=)
EP (1) EP1373308B1 (https=)
JP (1) JP4234999B2 (https=)
AT (1) ATE343591T1 (https=)
AU (1) AU2002307229B2 (https=)
CA (1) CA2442909C (https=)
DE (1) DE60215626T2 (https=)
WO (1) WO2002081504A2 (https=)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040082509A1 (en) 1999-10-12 2004-04-29 Christophe Bonny Cell-permeable peptide inhibitors of the JNK signal transduction pathway
US8183339B1 (en) 1999-10-12 2012-05-22 Xigen S.A. Cell-permeable peptide inhibitors of the JNK signal transduction pathway
US20030108539A1 (en) * 2000-02-14 2003-06-12 Christophe Bonny Cell-permeable peptide inhibitors of the JNK signal transduction pathway
US7138496B2 (en) * 2002-02-08 2006-11-21 Genetastix Corporation Human monoclonal antibodies against human CXCR4
WO2002068676A2 (en) * 2001-02-27 2002-09-06 University Of Rochester METHODS AND COMPOSITIONS FOR MODIFYING APOLIPOPROTEIN B mRNA EDITING
EP1373308B1 (en) 2001-04-06 2006-10-25 Thomas Jefferson University Antagonist for multimerization of hiv-1 vif protein
DK2093286T3 (da) 2001-10-01 2013-05-13 Dyax Corp Flerkædede, eukaryote displayvektorer og anvendelser deraf
WO2003057725A2 (en) * 2002-01-09 2003-07-17 University Of Lausanne Cell-permeable peptide inhibitors of the jnk signal transduction pathway
US20050123973A1 (en) * 2002-02-08 2005-06-09 Shaobing Hua Methods for generating monoclonal antibody against fusion protein containing peptide fragment derived from membrane protein
EP1575992A4 (en) * 2002-08-05 2007-02-21 Univ Rochester CHEMICAL PROTEINS FROM PROTEIN TRANSDUCATING DOMAIN / DEAMINASE, RELATED COMPOUNDS AND THEIR USES
US20040067532A1 (en) 2002-08-12 2004-04-08 Genetastix Corporation High throughput generation and affinity maturation of humanized antibody
US7220554B2 (en) * 2003-05-23 2007-05-22 Oregon Health And Science University Methods for identifying inhibitors
US20050014137A1 (en) * 2003-07-17 2005-01-20 Agouron Pharmaceuticals, Inc. Lentivirus assay system including Vif protein activity
CA2537798A1 (en) * 2003-09-03 2005-03-17 University Of Rochester Cytidine deaminase activators, deoxycytidine deaminase activators, vif antagonists, and methods of screening for molecules thereof
WO2005047483A2 (en) * 2003-11-12 2005-05-26 Medical Research Council Renta: an hiv immunogen and uses thereof
US8158770B2 (en) * 2004-05-06 2012-04-17 University Of Rochester Content dependent inhibitors of cytidine deaminases and uses thereof
CA2596448A1 (en) 2005-02-11 2006-08-11 University Of Rochester Methods and compositions related to heightened apobec-1 related protein (arp) expression
WO2007031098A1 (en) * 2005-09-12 2007-03-22 Xigen S.A. Cell-permeable peptide inhibitors of the jnk signal transduction pathway
US8080517B2 (en) * 2005-09-12 2011-12-20 Xigen Sa Cell-permeable peptide inhibitors of the JNK signal transduction pathway
CA2671410C (en) * 2006-12-06 2016-11-22 Thomas Jefferson University Peptide and treatment for hiv-1 infection
US8877688B2 (en) 2007-09-14 2014-11-04 Adimab, Llc Rationally designed, synthetic antibody libraries and uses therefor
EP3124497B1 (en) 2007-09-14 2020-04-15 Adimab, LLC Rationally designed, synthetic antibody libraries and uses therefor
US12529164B2 (en) 2007-09-14 2026-01-20 Adimab, Llc Rationally designed, synthetic antibody libraries and uses therefor
WO2009143864A1 (en) * 2008-05-30 2009-12-03 Xigen S.A. Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of chronic or non-chronic inflammatory digestive diseases
WO2009143865A1 (en) 2008-05-30 2009-12-03 Xigen S.A. Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases
WO2010072228A1 (en) 2008-12-22 2010-07-01 Xigen S.A. Novel transporter constructs and transporter cargo conjugate molecules
JP5457813B2 (ja) * 2009-12-16 2014-04-02 ルネサスエレクトロニクス株式会社 Ａｄｐｌｌ回路、半導体装置及び携帯情報機器
WO2011160653A1 (en) 2010-06-21 2011-12-29 Xigen S.A. Novel jnk inhibitor molecules
KR102318383B1 (ko) 2010-07-16 2021-10-27 아디맵 엘엘씨 항체 라이브러리
WO2012048721A1 (en) 2010-10-14 2012-04-19 Xigen S.A. Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of chronic or non-chronic inflammatory eye diseases
WO2013091670A1 (en) 2011-12-21 2013-06-27 Xigen S.A. Novel jnk inhibitor molecules for treatment of various diseases
WO2014055944A1 (en) * 2012-10-04 2014-04-10 Oyagen, Inc. Small molecules as anti-hiv agents that disrupt vif self-association and methods of use thereof
WO2014210082A2 (en) * 2013-06-24 2014-12-31 Oyagen, Inc. Camptothecin derivatives as anti-hiv agents and methods of identifying agents that disrupt vif self-association
KR20160023669A (ko) 2013-06-26 2016-03-03 자이겐 인플라메이션 리미티드 다양한 질병의 치료를 위한 jnk 신호 전달 경로의 세포 투과성 펩타이드 억제자의 새로운 용도
WO2014206427A1 (en) 2013-06-26 2014-12-31 Xigen Inflammation Ltd. New use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases
WO2015197097A1 (en) 2014-06-26 2015-12-30 Xigen Inflammation Ltd. New use for jnk inhibitor molecules for treatment of various diseases
CA3047000A1 (en) 2017-01-04 2018-07-12 Oyagen, Inc. Compounds, compositions, and methods for treating human immunodeficiency virus
EP3678699A1 (en) 2017-09-07 2020-07-15 University Of Oslo Vaccine molecules

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0330359A3 (en) * 1988-02-25 1991-06-05 Bio-Rad Laboratories, Inc. Composition useful in the diagnosis and treating of hiv-1 infection
AU7568794A (en) 1993-08-20 1995-03-21 St. Luke's-Roosevelt Hospital Center Hiv (vif)-related compositions, and prophylactic and therapeutic uses thereof
EP0980388A1 (en) 1997-05-20 2000-02-23 YISSUM RESEARCH DEVELOPMENT COMPANY of the Hebrew University of Jerusalem Vif-derived hiv protease inhibitors
EP0959136A1 (en) * 1998-05-20 1999-11-24 Introgene B.V. Targeted delivery through a cationic amino acid transporter
EP1373308B1 (en) 2001-04-06 2006-10-25 Thomas Jefferson University Antagonist for multimerization of hiv-1 vif protein

Also Published As

Publication number Publication date
ATE343591T1 (de) 2006-11-15
EP1373308A2 (en) 2004-01-02
CA2442909A1 (en) 2002-10-17
US6653443B2 (en) 2003-11-25
US20030013844A1 (en) 2003-01-16
US20040086512A1 (en) 2004-05-06
AU2002307229B2 (en) 2007-05-24
DE60215626T2 (de) 2007-08-30
JP4234999B2 (ja) 2009-03-04
WO2002081504A2 (en) 2002-10-17
EP1373308B1 (en) 2006-10-25
US20040146522A1 (en) 2004-07-29
US20080167199A1 (en) 2008-07-10
JP2005516885A (ja) 2005-06-09
US7226741B2 (en) 2007-06-05
US7498138B2 (en) 2009-03-03
DE60215626D1 (de) 2006-12-07
WO2002081504A3 (en) 2003-04-10

Similar Documents

Publication Publication Date Title
CA2442909C (en) Multimerization of hiv-1 vif protein as a therapeutic target
AU2002307229A1 (en) Multimerization of HIV-1 Vif protein as a therapeutic target
Bachand et al. Incorporation of Vpr into human immunodeficiency virus type 1 requires a direct interaction with the p6 domain of the p55 gag precursor
Bryant et al. Myristoylation-dependent replication and assembly of human immunodeficiency virus 1.
Saksela HIV-1 Nef and host cell protein kinases
JPH10506008A (ja) ＨＩＶ−１ Ｖｐｒ 融合分子に基づいたＨＩＶビリオン中へのタンパク質ターゲッティング
WO1990011359A1 (en) Intracellular method of inhibiting hiv in mammalian cells
US5874225A (en) Identification of compounds that modulate HIV-1 vpr protein activity
US7494767B2 (en) Assay for TSG101 as inhibitors of HIV production
CA2671410C (en) Peptide and treatment for hiv-1 infection
US6271354B1 (en) Chimeric viral proteins
AU2002303816A1 (en) TSG101 as inhibitors of HIV production
Rondon et al. Gene Therapy for HIV-1 Using Intracellular Antibodies Against HIV-1 Gag Proteins
CA2372456C (en) Viral infection inhibitor targeting integrase n-terminal domain
US6541002B1 (en) Compositions and methods for providing a protein to a virion
Janardhan Identification of immediate downstream effectors of HIV-1 Nef in T lymphocytes
Hodge Regulation of human immunodeficiency virus expression by viral and cellular factors

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20200831